Conference Coverage
Video
Elinor Ben-Menachem, MD
At the 67th Annual Meeting of the AAN, Dr. Ben-Menachem reviews drug choices for new-onset epilepsy.
Recommended Reading
Related Articles
Conference Coverage
-
Noninvasive testing in midlife flags late-onset epilepsy risk -
Novel neural cell therapy: A cure for focal epilepsy? -
Seizures in dementia hasten decline and death -
-
‘Striking’ rate of mental health comorbidities in epilepsy -
Significant racial disparities persist in status epilepticus -
-
-
Diazepam nasal spray effective in Lennox-Gastaut syndrome -
Literature Review
-
-
Modified Atkins diet beneficial in drug-resistant epilepsy -
-
Strong two-way link between epilepsy and depression -
High drug costs exclude most neurology patients from cutting-edge treatment -
Drug-resistant epilepsy needs earlier surgical referral -
‘Striking’ jump in cost of brand-name epilepsy meds -
Air pollution is a seizure trigger for patients with epilepsy -
New guidance on cannabis use for treatment-resistant epilepsy -
Question 1 of 5